X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.
Lead Product(s): CAR T-Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2023
Details:
The financing will be used to advance company's Generative AI pipeline of preclinical and clinical protein therapeutics, including GB-0669, a monoclonal antibody targeting a highly conserved region of the spike protein, in SARS-CoV-2.
Lead Product(s): GB-0669
Therapeutic Area: Infections and Infectious Diseases Product Name: GB-0669
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $273.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 14, 2023
Details:
The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s clinical research expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2023
Details:
Generate Biomedicine's integrated in silico design and wet lab capabilities combined with Amgen to harness its machine-learning-enabled technology to discover and develop protein therapeutics for five clinical targets across a range of therapeutic areas and modalities.
Lead Product(s): Engineered Protein-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,900.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration January 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
